Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Amgen Profits Drop Off 11%

October 26, 2010 7:32 am | by Matthew Perrone | News | Comments

Biotechnology company Amgen Inc. posted an 11 percent drop in third-quarter profit on flat sales and higher operating costs, although the drugmaker still beat expectations.


Bristol-Myers Income Drops 2%

October 26, 2010 7:30 am | by Linda A. Johnson | News | Comments

Bristol-Myers Squibb Co. posted a slight decline in third-quarter profit as its restrained spending was offset by flat sales of its drugs, lower income from its partners and bigger discounts to government due to the health care overhaul.


Rebif Significantly Slows MS Conversion

October 26, 2010 7:27 am | News | Comments

Merck KGaA announced that the two-year Phase 3 REFLEX study met its primary endpoint by demonstrating that Rebif (interferon beta-1a) significantly delayed conversion to multiple sclerosis diagnosed according to the McDonald criteria.


Hatchtech Raises Millions for Head Lice Trial

October 26, 2010 7:23 am | News | Comments

Venture-backed pharmaceutical company Hatchtech Pty Ltd has concluded a $6.3 million capital raising to conduct a Phase 2a clinical trial for its very promising head lice treatment.


ARIAD Announces Cancer Trial Results

October 26, 2010 7:19 am | News | Comments

ARIAD Pharmaceuticals, Inc. announced interim results of a randomized, open-label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer.


Shire Receives Paragraph IV Notice from Watson

October 26, 2010 7:12 am | News | Comments

Shire plc announces that it has received a Paragraph IV Notice Letter from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of Shire’s 4 mg guanfacine hydrochloride extended release tablet, INTUNIV.


PTC Beginning Phase 2 Trial of Ataluren

October 26, 2010 7:10 am | News | Comments

PTC Therapeutics, Inc. announced that it is expanding the development of ataluren, an investigational new drug, with the initiation of a Phase 2 clinical trial in nonsense mutation methylmalonic acidemia.


Rockland Receives NIH Antibody Grant

October 26, 2010 7:07 am | News | Comments

Rockland Immunochemicals Inc. announced that it has received a Phase 1 Small Business Innovation Research grant from the National Institutes of Health to develop generic antibodies “biosimilars” for the treatment of cancer.


Agile Contraceptive Patch Equal to Pills

October 26, 2010 7:04 am | News | Comments

Agile Therapeutics announced results from a Phase 2 clinical study of AG200-15, Agile’s weekly contraceptive patch containing ethinyl estradiol in combination with levonorgestrel.


Flow Cytometry Analysis Software

October 25, 2010 8:49 am | Product Releases | Comments

Beckman Coulter, Inc.’s flow cytometry analysis software, Kaluza 1.1, processes multicolor files of up to 10 million events in real time and offers an analytical speed that is several hundred times faster than other commercially available software.


HPLC Columns

October 25, 2010 8:42 am | Product Releases | Comments

Tosoh Corporation announced several high performance liquid chromatography columns for the analysis of water-soluble polymers, as well as a column designed for the simultaneous separation of an active pharmaceutical ingredient and its counterions.


Scientists Pave Way for Pulmonary Hypertension Treatment

October 25, 2010 8:15 am | News | Comments

A researcher has discovered what could be the first truly effective breakthrough in the diagnosis and treatment of pulmonary hypertension, a devastating, life-threatening condition which results in an enlargement of the heart.


Scientists Find Neurons Act Like Dominos

October 25, 2010 8:11 am | News | Comments

By studying the brain circuits that control bird song, MIT researchers have identified a "chain reaction" of brain activity that appears to control the timing of song.


Antigenics Expands Phase 2 Study of HSPPC-96

October 25, 2010 8:04 am | News | Comments

Antigenics, Inc. announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage vaccine; vitespen), Antigenics' personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.


Novartis Submitting sBLA for Menveo

October 25, 2010 8:01 am | News | Comments

New Phase 3 data indicate that Menveo demonstrated robust immunogenicity in infants potentially offering protection against four major serogroups of meningococcal disease.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.